Avelumab: A Review in Metastatic Merkel Cell Carcinoma
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that is directed against programmed cell death ligand 1 (PD-L1). Avelumab functions as an immune checkpoint inhibitor and has recently been approved in the USA, the EU and Japan for the treatment of metastatic Merkel cell carcinoma (MCC). It is thus the first therapeutic agent specifically approved for use in this indication, and is approved for use independent of line of treatment. Approval for avelumab in metastatic MCC was based on the two-part, single-arm, phase II trial, JAVELIN Merkel 200. In Part A of the study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab. The responses were observed early and appeared to be durable, with an estimated 74% of responses having a duration ≥ 12 months. Furthermore, interim results from a separate cohort of patients (Part B) indicate an objective response rate for avelumab of > 60% in patients who were chemotherapy-naïve in the metastatic disease setting. Avelumab is associated with a risk of immune-related adverse events but, overall, has an acceptable and manageable safety and tolerability profile. In conclusion, currently available data suggest that avelumab presents a clinically beneficial new treatment option for metastatic MCC, a rare but aggressive cancer associated with a poor prognosis.
During the peer review process, the manufacturer of avelumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of Interest
Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 5.Cassler NM, Merrill D, Bichakjian CK, et al. Merkel cell carcinoma therapeutic update. Curr Treat Options in Oncol. 2016;17(36)Google Scholar
- 8.National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology (NCCN guidelines®): Merkel cell carcinoma - version 1.2018. 2017. https://www.nccn.org/. Accessed 20 Apr 2018.
- 11.Webb ES, Liu P, Baleeiro R, et al. Immune checkpoint inhibitors in cancer therapy. J Biomed Res. 2017; http://journal.hep.com.cn/jbr/EN/10.7555/JBR.31.20160168#1.
- 16.European Medicines Agency. Bavencio (avelumab): summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 20 Apr 2018.
- 17.US FDA. Bavencio® (avelumab): US prescribing information. 2017. www.fda.gov/. Accessed 20 Apr 2018.
- 18.Pharmaceuticals and Medical Devices Agency (Japan). Bavencio® (avelumab): Japanese prescribing information. 2017. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/380079_4291438A1022_1_01. Accessed 30 Apr 2018.
- 23.European Medicines Agency. European public assessment report: Bavencio (avelumab). 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004338/WC500236649.pdf. Accessed 20 Apr 2018.
- 24.D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.0077.
- 27.D'Angelo SP, Russell JS, Bhatia S, et al. 18-month efficacy and safety update from JAVELIN Merkel 200 part A: a phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy [abstract no. 192 plus poster]. J Clin Oncol. 2018;36(Suppl 5S).Google Scholar
- 28.Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010-17.Google Scholar